ArticleVaccines2025

Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.

Fengcai Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.